InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Altman Michael Seth. Insider active across 5 companies, notably Nautilus Biotechnology, Inc.. In total, 5 disclosures have been logged. History available since 15 July 2021. The latest transaction was disclosed on 13 June 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Altman Michael Seth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
2,066,250 股Common StockSEC:0001746738-26-000003:0
499,000 股Class A ordinary sharesSEC:0001140361-24-035164:0
286,250 股@ US$10.00100.0% 占其流量Class A ordinary sharesSEC:0001140361-24-030023:0
499,000 股@ US$10.00100.0% 占其流量Class A ordinary sharesSEC:0001140361-21-024476:0
3,647,500 股Common StockSEC:0001140361-21-020674:0
5 条申报中的 5 条
About Altman Michael Seth
ALTMAN MICHAEL SETH is a declarant with 6 filings in total. The sampled recent filings run from 2021-06-11 to 2024-07-31, with a modal transaction nature shown as Attribution; the buy and sell amounts are both 0 in this recent sample. He is listed as Chief Financial Officer at ARYA Sciences Acquisition Corp V, Director at Nautilus Biotechnology, Inc., Chief Financial Officer at ARYA Sciences Acquisition Corp IV, and Chief Business Officer at Perceptive Capital Solutions Corp.
